Malcolm Weir
Overview
Explore the profile of Malcolm Weir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brown A, Bradley S, Marshall F, Brown G, Bennett K, Brown J, et al.
Cell
. 2021 Nov;
184(24):5886-5901.e22.
PMID: 34822784
Current therapies for Alzheimer's disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy. An alternative...
2.
Bakker C, Prins S, Liptrot J, Hart E, Klaassen E, Brown G, et al.
Br J Clin Pharmacol
. 2021 Apr;
87(11):4439-4449.
PMID: 33891333
Aims: HTL0009936 is a selective M muscarinic receptor agonist in development for cognitive dysfunction in Alzheimer's disease. Safety, tolerability and pharmacokinetics and exploratory pharmacodynamic effects of HTL0009936 administered by continuous...
3.
Bakker C, Tasker T, Liptrot J, Hart E, Klaassen E, Doll R, et al.
Alzheimers Res Ther
. 2021 Apr;
13(1):87.
PMID: 33883008
Background: The cholinergic system and M receptor remain an important target for symptomatic treatment of cognitive dysfunction. The selective M receptor partial agonist HTL0018318 is under development for the symptomatic...
4.
Bakker C, Tasker T, Liptrot J, Hart E, Klaassen E, Prins S, et al.
Br J Clin Pharmacol
. 2020 Dec;
87(7):2945-2955.
PMID: 33351971
Aims: HTL0018318 is a selective M receptor partial agonist currently under development for the symptomatic treatment of cognitive and behavioural symptoms in Alzheimer's disease and other dementias. We investigated safety,...
5.
Rappas M, Ali A, Bennett K, Brown J, Bucknell S, Congreve M, et al.
J Med Chem
. 2019 Dec;
63(4):1528-1543.
PMID: 31860301
The orexin system, which consists of the two G protein-coupled receptors OX and OX, activated by the neuropeptides OX-A and OX-B, is firmly established as a key regulator of behavioral...
6.
OBrien A, Andrews S, Baig A, Bortolato A, Brown A, Brown G, et al.
Bioorg Med Chem Lett
. 2019 Aug;
29(20):126611.
PMID: 31447084
A series of novel allosteric antagonists of the GLP-1 receptor (GLP-1R), exemplified by HTL26119, are described. SBDD approaches were employed to identify HTL26119, exploiting structural understanding of the allosteric binding...
7.
Jazayeri A, Rappas M, Brown A, Kean J, Errey J, Robertson N, et al.
Nature
. 2017 Jul;
548(7665):122.
PMID: 28700581
This corrects the article DOI: 10.1038/nature22800.
8.
Jazayeri A, Rappas M, Brown A, Kean J, Errey J, Robertson N, et al.
Nature
. 2017 Jun;
546(7657):254-258.
PMID: 28562585
Glucagon-like peptide 1 (GLP-1) regulates glucose homeostasis through the control of insulin release from the pancreas. GLP-1 peptide agonists are efficacious drugs for the treatment of diabetes. To gain insight...
9.
Jazayeri A, Dore A, Lamb D, Krishnamurthy H, Southall S, Baig A, et al.
Nature
. 2016 Apr;
533(7602):274-7.
PMID: 27111510
Glucagon is a 29-amino-acid peptide released from the α-cells of the islet of Langerhans, which has a key role in glucose homeostasis. Glucagon action is transduced by the class B...
10.
Dore A, Okrasa K, Patel J, Serrano-Vega M, Bennett K, Cooke R, et al.
Nature
. 2014 Jul;
511(7511):557-62.
PMID: 25042998
Metabotropic glutamate receptors are class C G-protein-coupled receptors which respond to the neurotransmitter glutamate. Structural studies have been restricted to the amino-terminal extracellular domain, providing little understanding of the membrane-spanning...